Recent
Press Releases:
- Aug 22, 2008
- Feb 11, 2008
- Jan 25, 2008
- Jan 24, 2008
- Jan 17, 2008
- Jan 11, 2007
- Nov 15, 2006
- Oct 2, 2006
- Jul 5, 2006
- Apr 4, 2006
- Feb 16, 2006
- Jan 24, 2006
- Sep 14, 2005
- Aug 9, 2005
- May 13, 2005
- May 4, 2005
- March 22, 2005
Upcoming Events |
OFFICIAL RELEASE
Ash
Access Technology’s Investigational Antimicrobial/Anthithrombotic
Therapy Shows Significant Promise in Pre-clinical Trials for Preventing
Catheter-Related Bloodstream Infections
AAT-023 Demonstrates Rapid, Broad Spectrum Efficacy Against Common
Bacteria Strains Associated With Deadly Infections
Wednesday, May 4, 2005 7:17 AM EDT - - - (Lafayette,
Indiana) Ash
Access Technology, Inc., has released pre-clinical laboratory results
that demonstrate the effectiveness of their emerging antimicrobial
/ antithrombotic therapy, AAT-023, for the prevention and treatment
of catheter-related bloodstream infections (CRBSI).
According to the Centers for Disease Control, the magnitude of CRBSI
in the U.S is significant with an estimated 200,000 to 400,000 episodes
annually. Studies have shown that mortality rates associated with
CRBSI range from 12 – 25% while annual healthcare costs for
treating these infections may exceed $2 billion.
In the pre-clinical tests, AAT-023 was studied along with heparin
to evaluate the antimicrobial efficacy (time and duration of complete
pathogen eradication) against both gram positive and gram negative
strains of bacteria. Testing was done under rigorous conditions to
simulate as best as possible the environment of a central venous
catheter. High concentrations of bacteria were exposed to growth
medium and then placed in heparin and AAT-023. The heparin arm showed
little to no efficacy for all bacteria and times tested. AAT-023,
on the other hand, showed significant efficacy against most organisms
at 60 minutes and “complete eradication” for all tested
pathogens at 24 hours, 48 hours, and 72 hours respectively. Table
1 below highlights the antimicrobial results for both AAT-023 and
Heparin. Microbes tested in the pre-clinical laboratory study included
all organisms associated with catheter-related bloodstream infections
such as Staphylococcus aureus and epidermis, Enterococcus faecalis,
Escherichia coli, Pseudomonas aeruginosa, and Candida albicans.
The FDA granted approval last month for an AAT-023 pivotal clinical
trial to be completed at a later date. The study will evaluate the
efficacy and safety of AAT-023 vs. heparin in the prevention and
treatment of CRBSI. The patient population to be enrolled in the
trial will be hemodialysis patients who are using a central venous
catheter (CVCD) for their vascular access.
Antimicrobial Effectiveness
Rapid and Broad-Based Kill Profile
Heparin
(Baseline) |
|
60 min |
24 hr |
48 hr |
72 hr |
S. aureus 33591 |
|
|
|
|
S. epidermidis 12228 |
|
|
|
|
E. faecalis 376 |
|
|
|
|
E. coli 25922 |
|
|
|
|
E. coli 35218 |
|
|
|
|
P. aerug 27853 |
|
|
|
|
C. albicans 10231 |
|
|
|
|
Zuragen™
(Zuragen™) |
|
60 min |
24 hr |
48 hr |
72 hr |
S. aureus 33591 |
|
|
|
|
S. epidermidis 2228 |
|
|
|
|
E. faecalis 376 |
|
|
|
|
E. coli 25922 |
|
|
|
|
E. coli 35218 |
|
|
|
|
P. aerug 27853 |
|
|
|
|
C. albicans 10231 |
|
|
|
|
Fully
Alive |
|
-3-4 Log
Kill |
|
Complete
Kill |
Ash Access Technology, Inc. is a privately-held
company founded to develop antimicrobial and vascular access technologies,
devices and methodologies to combat the deadly and expensive problem
of catheter-related bloodstream infections, with an emphasis on prevention.
Dr. Stephen A. Ash, Chairman and Director, Research and Development,
is a practicing Nephrologist with the Arnett Clinic in Lafayette,
Indiana, and is a world-recognized researcher and patent holder in
extracorporeal devices, sorbent chemistry, and vascular and peritoneal
access devices. Ash Access Technology is located in Lafayette, Indiana
in the INOK Business Center.
This press release contains forward-looking statements, which if
not based on historical facts, involve risks and uncertainties. Our
actual results may differ materially from the results or events stated
in the forward-looking statements, including, but not limited to,
certain events not within the Company's control. |